Pozanicline Hydrochloride

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NamePozanicline Hydrochloride

Drug Alias NamePozaniclina帕扎克兰盐酸盐珀扎克兰盐酸盐Pozaniclinum盐酸帕扎克兰 +[10]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionNeuronal acetylcholine receptor protein alpha-7 subunit agonistsNeuronal acetylcholine receptor; alpha3/beta4 antagonistsNicotinic acetylcholine receptor alpha4/beta2/alpha5 agonists

TargetsNicotinic acetylcholine receptor alpha4/beta2/alpha5Neuronal acetylcholine receptor protein alpha-7 subunitNeuronal acetylcholine receptor; alpha3/beta4

Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityTobacco Use DisorderAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbott Laboratories Abbvie Inc University Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsAttention Deficit Disorder with HyperactivityTobacco Use DisorderAlzheimer Disease

Other Information

ATC CodeN/A